New trial aims to find best treatment for lung complication in rheumatoid arthritis

NCT ID NCT07643038

Not yet recruiting Disease control Sponsor: Chinese SLE Treatment And Research Group Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This 52-week study will compare three drugs—tocilizumab, telitacicept, and methotrexate—in 204 people with rheumatoid arthritis who also have interstitial lung disease. The main goal is to see which drug best improves lung function. Participants will continue their usual arthritis medications during the trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tocilizumab, telitacicept, and methotrexate
What this could lead to: If successful, this trial could identify a better treatment option for people with rheumatoid arthritis who also have lung disease, potentially slowing lung damage and improving breathing.
What could go wrong: This is a phase 4 study, so the drugs are already approved for other uses, but their effectiveness for this specific lung condition is unproven. The trial is not yet recruiting, and results may show no clear benefit or unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis-associated interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE

Contacts and locations

Locations

Affiliated Hospital of Inner Mongolia Medical University

Hohhot, China
Affiliated Hospital of Yan'an University

Yan’an, China
Beijing Chao-Yang Hospital, Capital Medical University

Beijing, China
China-Japan Friendship Hospital

Beijing, China
China-Japan Union Hospital of Jilin University

Changchun, China
Handan Central Hospital

Handan, China
Jiujiang No. 1 People's Hospital

Jiujiang, China
Peking Union Medical College Hospital

Beijing, China
People's Hospital of Ningxia Hui Autonomous Region

Yinchuan, China
Shanxi Bethune Hospital

Taiyuan, China
The First Affiliated Hospital of Anhui Medical University

Hefei, China
The First Affiliated Hospital of Army Medical University (Southwest Hospital)

Chongqing, China
The First Affiliated Hospital of Guangxi Medical University

Nanning, China
The First Affiliated Hospital of Henan University of Science and Technology

Luoyang, Henan, China
The First Affiliated Hospital of Nanjing Medical University

Nanjing, China
The First Affiliated Hospital of Xinjiang Medical University

Ürümqi, China
The Second Affiliated Hospital of Dalian Medical University

Dalian, China
The Second Affiliated Hospital of Nanchang University

Nanchang, China
The Second Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, China
The Second Hospital of Lanzhou University

Lanzhou, China
Xingyi People's Hospital

Xingyi, China
Xuanwu Hospital, Capital Medical University

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.